Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Conditions:   GEP-NET;   Gastroenteropancreatic Neuroendocrine Tumor;   Gastroenteropancreatic Neuroendocrine Tumor Disease;   Neuroendocrine Tumors;   Carcinoid;   Carcinoid Tumor;   Pancreatic NET
Interventions:   Drug: RYZ101;   Drug: Everolimus 10 mg;   Drug: Sunitinib 37.5 MG;   Drug: Octreotide LAR 60 MG Injection;   Drug: Lanreotide 120Mg Sa Susp Inj Syringe
Sponsor:   RayzeBio, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 29, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments